Back to today’s briefing

Story perspectives

Biogen Targets Sage Therapeutics Amid Acquisition Plans

1/13/2025

34 5

Summary

Story summary

Biogen aims for more biotech acquisitions in 2025, as stated by CEO Chris Viehbacher.
The company proposed a $469 million acquisition of Sage Therapeutics, its partner on Zurzuvae for postpartum depression.
With Sage holding $569 million in cash reserves, Biogen's offer seems undervalued.
Recent clinical setbacks have diminished Sage's leverage in negotiations.

1 of 1

Story summary

Biogen aims for more biotech acquisitions in 2025, as stated by CEO Chris Viehbacher.
The company proposed a $469 million acquisition of Sage Therapeutics, its partner on Zurzuvae for postpartum depression.
With Sage holding $569 million in cash reserves, Biogen's offer seems undervalued.
Recent clinical setbacks have diminished Sage's leverage in negotiations.